Canakinumab | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Canakinumab
Health Canada Patents

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

Contact Supplier

IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.

Contact Supplier

IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

Contact Supplier

medac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

Contact Supplier

Coral

Contact Supplier

ICE Pharma offers a unique range of bile acid products and best-in-class services for the pharmaceutical industry.

Contact Supplier

Canakinumab

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

65 Drugs in Development

65 Drugs in Development

FINISHED DOSAGE FORMULATIONS

6 FDF Dossiers, 1 FDA Orange Book, 4 Europe, 1 Canada

6 FDF Dossiers
1 FDA Orange Book
4 Europe
1 Canada

DIGITAL CONTENT

22 News #PharmaBuzz

22 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 11 Annual Reports

1 US Medicaid Prescriptions
11 Annual Reports

PATENTS & EXCLUSIVITIES

11 Health Canada Patents

11 Health Canada Patents

Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

11 All

01 11Gowling WLG (Canada) LLP

filter Patent Reset all filters

11 All

01 22420231

02 12626214

03 22687499

04 12745938

05 22898369

06 22947947

07 12993565

filter Product Reset all filters

11 All

01 6CANAKINUMAB

02 5Canakinumab

filter Dosage Reset all filters

11 All

01 5POWDER FOR SOLUTION

02 6SOLUTION

filter Exp Date Reset all filters

11 All

01 22021-08-20

02 32026-10-24

03 52028-05-28

04 12029-12-09

Product Main Page

01

Gowling WLG (Canada) LLP

Canakinumab

Formnext Forum

Not Confirmed

Gowling WLG (Canada) LLP

Canada

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2021-08-20

Date Granted : 2011-04-26

Canakinumab

Brand Name : ILARIS

Patent Number : 2420231

Filing Date : 2001-08-20

Strength per Unit : 150 mg / mL

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : Subcutaneous

Patent Expiration Date : 2021-08-20

Date Granted : 2011-04-26

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Gowling WLG (Canada) LLP

Canakinumab

Formnext Forum

Not Confirmed

Gowling WLG (Canada) LLP

Canada

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-10-24

Date Granted : 2016-06-21

Canakinumab

Brand Name : ILARIS

Patent Number : 2626214

Filing Date : 2006-10-24

Strength per Unit : 150 mg / mL

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : Subcutaneous

Patent Expiration Date : 2026-10-24

Date Granted : 2016-06-21

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Gowling WLG (Canada) LLP

CANAKINUMAB

Formnext Forum

Not Confirmed

Gowling WLG (Canada) LLP

Canada

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2021-08-20

Date Granted : 2011-04-26

CANAKINUMAB

Brand Name : ILARIS

Patent Number : 2420231

Filing Date : 2001-08-20

Strength per Unit : 150 mg / 1mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2021-08-20

Date Granted : 2011-04-26

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

Gowling WLG (Canada) LLP

Canakinumab

Formnext Forum

Not Confirmed

Gowling WLG (Canada) LLP

Country

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-10-24

Date Granted : 2017-06-20

Canakinumab

Brand Name : ILARIS

Patent Number : 2898369

Filing Date : 2006-10-24

Strength per Unit : 150 mg / mL

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : Subcutaneous

Patent Expiration Date : 2026-10-24

Date Granted : 2017-06-20

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

05

Gowling WLG (Canada) LLP

Canakinumab

Formnext Forum

Not Confirmed

Gowling WLG (Canada) LLP

Country

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-05-28

Date Granted : 2017-11-28

Canakinumab

Brand Name : ILARIS

Patent Number : 2687499

Filing Date : 2008-05-28

Strength per Unit : 150 mg / mL

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : Subcutaneous

Patent Expiration Date : 2028-05-28

Date Granted : 2017-11-28

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

06

Gowling WLG (Canada) LLP

Canakinumab

Formnext Forum

Not Confirmed

Gowling WLG (Canada) LLP

Country

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-05-28

Date Granted : 2018-03-06

Canakinumab

Brand Name : ILARIS

Patent Number : 2947947

Filing Date : 2008-05-28

Strength per Unit : 150 mg / mL

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : Subcutaneous

Patent Expiration Date : 2028-05-28

Date Granted : 2018-03-06

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

07

Gowling WLG (Canada) LLP

CANAKINUMAB

Formnext Forum

Not Confirmed

Gowling WLG (Canada) LLP

Country

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-10-24

Date Granted : 2017-06-20

CANAKINUMAB

Brand Name : ILARIS

Patent Number : 2898369

Filing Date : 2006-10-24

Strength per Unit : 150 mg / 1mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2026-10-24

Date Granted : 2017-06-20

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

08

Gowling WLG (Canada) LLP

CANAKINUMAB

Formnext Forum

Not Confirmed

Gowling WLG (Canada) LLP

Country

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-05-28

Date Granted : 2017-11-28

CANAKINUMAB

Brand Name : ILARIS

Patent Number : 2687499

Filing Date : 2008-05-28

Strength per Unit : 150 mg / 1mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2028-05-28

Date Granted : 2017-11-28

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

09

Gowling WLG (Canada) LLP

CANAKINUMAB

Formnext Forum

Not Confirmed

Gowling WLG (Canada) LLP

Country

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-05-28

Date Granted : 2018-03-06

CANAKINUMAB

Brand Name : ILARIS

Patent Number : 2947947

Filing Date : 2008-05-28

Strength per Unit : 150 mg / 1mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2028-05-28

Date Granted : 2018-03-06

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

10

Gowling WLG (Canada) LLP

CANAKINUMAB

Formnext Forum

Not Confirmed

Gowling WLG (Canada) LLP

Country

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-12-09

Date Granted : 2018-04-24

CANAKINUMAB

Brand Name : ILARIS

Patent Number : 2745938

Filing Date : 2009-12-09

Strength per Unit : 150 mg / 1mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2029-12-09

Date Granted : 2018-04-24

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

1
2

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!